Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TCR alpha/beta+/CD19+ depleted hematopoietic cells |
Synonyms | |
Therapy Description |
TCR alpha/beta+/CD19+ depleted hematopoietic cells is a preparation of donor hematopoietic progenitor cells that have been treated to remove the CD19 and TCRalpha/beta-expressing populations, potentially resulting in decreased graft vs. host disease after transplantation (PMID: 27811849, PMID: 29431621). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TCR alpha/beta+/CD19+ depleted hematopoietic cells | TCR alpha/beta+/CD19+ depleted HPCs||TCR alpha/beta/CD19-depleted HPCs | TCR alpha/beta+/CD19+ depleted hematopoietic cells is a preparation of donor hematopoietic progenitor cells that have been treated to remove the CD19 and TCRalpha/beta-expressing populations, potentially resulting in decreased graft vs. host disease after transplantation (PMID: 27811849, PMID: 29431621). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03849651 | Phase II | TCR alpha/beta+/CD19+ depleted hematopoietic cells CD45RA-depleted donor lymphocytes anti-thymocyte globulin + Cyclophosphamide + Filgrastim + Fludarabine + Melphalan + Mesna + Thiotepa Blinatumomab | TCRalphabeta-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | Active, not recruiting | USA | 0 |